Literature DB >> 12130566

Pituitary hypoplasia and lactotroph dysfunction in mice deficient for cyclin-dependent kinase-4.

David S Moons1, Siwanon Jirawatnotai, A F Parlow, Geula Gibori, Rhonda D Kineman, Hiroaki Kiyokawa.   

Abstract

The lactotroph undergoes dynamic regulation of cell cycle progression during pregnancy, as well as throughout the development of the pituitary. We recently reported that female mice with targeted disruption of Cdk4, one of the G(1)-regulatory cyclin-dependent kinases, are unable to support embryo implantation because of defective progesterone secretion from the corpus luteum. In this study, we demonstrate that this phenotype is not attributable to a primary defect in the corpus luteum but is a consequence of defective prolactin (PRL) production caused by inappropriate development of the pituitary lactotroph population. Specifically, the pituitary of Cdk4-deficient mice is extremely hypoplastic. Lactotrophs and somatotrophs of prepubertal Cdk4-deficient mice were 80% decreased in number, relative to those in wild-type mice, whereas gonadotrophs were unaffected. Lactotrophs of Cdk4-deficient mice did not proliferate in response to estrogen administration, whereas estrogen could induce the expression of galanin, an estrogen-responsive factor required for lactotroph proliferation. The reduction in lactotroph numbers was reflected by markedly diminished serum PRL levels in both prepubertal and postcoital Cdk4-deficient mice. Administration of PRL, after mating, significantly increased serum progesterone levels and restored implantation in Cdk4-deficient female mice. These observations demonstrate that Cdk4 is required for normal proliferation of the lactotroph population.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12130566     DOI: 10.1210/endo.143.8.8956

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  27 in total

1.  p19Ink4d is a tumor suppressor and controls pituitary anterior lobe cell proliferation.

Authors:  Feng Bai; Ho Lam Chan; Matthew D Smith; Hiroaki Kiyokawa; Xin-Hai Pei
Journal:  Mol Cell Biol       Date:  2014-03-31       Impact factor: 4.272

Review 2.  Pathogenesis of pituitary tumors.

Authors:  Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

3.  Lhx4 deficiency: increased cyclin-dependent kinase inhibitor expression and pituitary hypoplasia.

Authors:  Peter Gergics; Michelle L Brinkmeier; Sally A Camper
Journal:  Mol Endocrinol       Date:  2015-02-10

Review 4.  Functional evolution of cyclin-dependent kinases.

Authors:  John H Doonan; Georgios Kitsios
Journal:  Mol Biotechnol       Date:  2009-01-15       Impact factor: 2.695

Review 5.  Pituitary gland development and disease: from stem cell to hormone production.

Authors:  Shannon W Davis; Buffy S Ellsworth; María Inés Peréz Millan; Peter Gergics; Vanessa Schade; Nastaran Foyouzi; Michelle L Brinkmeier; Amanda H Mortensen; Sally A Camper
Journal:  Curr Top Dev Biol       Date:  2013       Impact factor: 4.897

Review 6.  Cell cycle, CDKs and cancer: a changing paradigm.

Authors:  Marcos Malumbres; Mariano Barbacid
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

7.  The Balance of PI3K and ERK Signaling Is Dysregulated in Prolactinoma and Modulated by Dopamine.

Authors:  Allyson K Roof; Siwanon Jirawatnotai; Tammy Trudeau; Crystal Kuzyk; Margaret E Wierman; Hiroaki Kiyokawa; Arthur Gutierrez-Hartmann
Journal:  Endocrinology       Date:  2018-06-01       Impact factor: 4.736

8.  Genetic evidence for functional dependency of p18Ink4c on Cdk4.

Authors:  Xin-Hai Pei; Feng Bai; Tateki Tsutsui; Hiroaki Kiyokawa; Yue Xiong
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

Review 9.  Mechanisms for pituitary tumorigenesis: the plastic pituitary.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

10.  Mice thrive without Cdk4 and Cdk2.

Authors:  Cédric Barrière; David Santamaría; Antonio Cerqueira; Javier Galán; Alberto Martín; Sagrario Ortega; Marcos Malumbres; Pierre Dubus; Mariano Barbacid
Journal:  Mol Oncol       Date:  2007-03-14       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.